Form 4: Orchestra BioMed Schedules 120K RSU Award for COO

Orchestra BioMed Holdings, Inc. disclosed a future grant of 120,000 restricted stock units to President and Chief Operating Officer Darren Sherman, vesting over three years.

Summary

• Darren Sherman, President and Chief Operating Officer of Orchestra BioMed Holdings, Inc. (OBIO), is scheduled to be awarded 120,000 restricted stock units (RSUs) on August 7, 2025.
• Each RSU represents a contingent right to receive one share of Common Stock.
• The RSUs are set to vest in three tranches: 33.33% after 24 months (August 7, 2027), 33.33% after 30 months (February 7, 2028), and 33.34% after 36 months (August 7, 2028), contingent on continuous service.
• Following this future transaction, Darren Sherman's beneficial ownership is reported as 923,837 shares of Common Stock.

Sentiment

Score: 7

Explanation: The scheduled future award of restricted stock units to a key executive is generally a positive sign for executive retention and alignment with shareholder interests, though it introduces future dilution. The reporting of a future transaction date is unusual but explicitly stated.

Positives

• The future RSU award aligns the interests of President and COO Darren Sherman with shareholders, incentivizing long-term performance and retention.
• The vesting schedule over three years promotes sustained commitment from a key executive.

Negatives

• The future issuance of 120,000 restricted stock units will result in dilution for existing shareholders upon their vesting.

Risks

• Future dilution of existing shareholders upon the vesting of the 120,000 restricted stock units.
• The vesting of RSUs is contingent on the Reporting Person's continuous service, meaning the company risks losing the executive if service is not maintained prior to the future grant date or during the vesting period.

Future Outlook

The filing indicates a future equity award to a key executive, signaling a long-term incentive strategy. It does not provide broader forward-looking statements or guidance beyond the vesting schedule of the awarded restricted stock units.

Industry Context

This filing is a standard disclosure of executive compensation in the form of equity awards, a common practice across industries to align executive incentives with shareholder value. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Potential future dilution upon vesting of RSUs, but also improved executive retention and alignment of interests. The reporting of a future transaction provides advance notice of this compensation event.
• Employees: No direct impact mentioned, but executive compensation practices can influence overall company culture and compensation philosophy.
• Executive (Darren Sherman): Is set to receive a significant equity award, which will increase his beneficial ownership and long-term incentive upon the grant date.

Next Steps

• Vesting of 33.33% of RSUs on August 7, 2027.
• Vesting of 33.33% of RSUs on February 7, 2028.
• Vesting of 33.34% of RSUs on August 7, 2028.

Key Dates

Keywords

Orchestra BioMed, OBIO, Darren Sherman, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Form 4, Equity Award, Corporate Governance